image credit: Pxfuel

ViroCell Biologics and GOSH to address gene and cell therapy “logjam”

ViroCell Biologics and Great Ormond Street Hospital for Children (GOSH) have today announced a new partnership that will immediately address the global viral vector manufacturing bottleneck for clinical trials.

Viral vectors are high-value delivery vehicles used to make cell and gene therapies, and their availability and effectiveness governs the clinical success of the treatment. There is currently a global viral vector supply demand imbalance that constrains the manufacture of novel cell and gene therapies. ViroCell, a contract development and manufacturing organisation (CDMO), is focused where the viral vector design and good manufacturing practice (GMP) manufacturing bottleneck is most acute: the zone between pre-clinical concept and clinical trials.

Read More on European Pharmaceutical Review